Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Vanguard Real Estate Index Fund ETF (VNQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Vanguard Real Estate Index Fund ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.83 (market cap $4.49B), while Vanguard Real Estate Index Fund ETF trades at $96.97. The key difference: Vanguard Real Estate Index Fund ETF is trading nearer its 52-week high, ACADIA Pharmaceuticals Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | VNQ | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | — |
52-Week High | $28.06 | $98.66 |
52-Week Low | $20.06 | $87.00 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
VNQ (Vanguard Real Estate ETF) trades at $97.24, down 0.8% on the day, with technical indicators showing a bullish trend supported by moving averages. The ETF's recent performance reflects renewed investor interest in REITs amid shifting rate expectations, with June 2026 marking the sector's best monthly performance in years according to market data. Dividend payments remain a key attraction, with the next distribution scheduled for June 2026.
The outlook for VNQ appears cautiously optimistic as REIT fundamentals show resilience despite elevated interest rates. Investment opportunity lies in potential rate stabilization and sector rotation, while risks include persistent inflation pressure and Treasury yield volatility. Analyst sentiment is mixed, with some highlighting discounted valuations while others caution about sector-specific challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →
